Bi-digital O-ring Test (BDORT), Coupled with Molecular Docking Analysis, for Improving Parathyroid Gland Health: Clinical Insights into Combined Oils Therapy for Treating Hyper-Parathyroidism

Introduction: Hyperparathyroidism, characterized by elevated parathyroid hormone (PTH) levels, predominantly affects women aged 50 to 60 years. Traditional treatments, such as parathyroidectomy and calcimimetics, pose risks including hypocalcemia and gastrointestinal issues. This study evaluates a novel treatment using plant-derived oils, comparing its efficacy to conventional therapies. Materials and Methods: Over 5 years, 3,230 subjects were examined using BDORT. Among them, 51 were diagnosed with hyperparathyroidism, with 30 exhibiting elevated PTH levels. Fourteen patients (12 females, 2 males) were treated with Parathyroid Recovery , an oil mixture formulated via BDORT. PTH levels were measured pre- and post-treatment. Molecular docking studies assessed the binding affinities of traditional drugs (Cinacalcet, Teriparatide) and natural compounds (Capsorubin, Quercetin-3-Rutinoside) from the oil blend to the calcium-sensing receptor (CaSR). Results: The plant oil mixture significantly reduced PTH levels, with an average decrease of 18.97 pg/mL ( ρ < 0.002, ***). Molecular docking revealed that Capsorubin and Quercetin-3-Rutinoside exhibited stronger binding affinities to CaSR (−6.9 kcal/mol) than conventional drugs. A strong negative correlation (≈ −0.77) was observed between Vitamin D levels and pre-treatment PTH levels, emphasizing Vitamin D's role in hyperparathyroidism management. Discussion and Conclusions: The superior CaSR binding affinities of Capsorubin and Quercetin-3-Rutinoside correlate with clinical PTH reductions, suggesting enhanced therapeutic efficacy. Older patients exhibited greater responsiveness. BDORT proves valuable for both diagnosis and treatment formulation. These findings support plant-derived oils as a promising alternative to conventional therapies. Future research should validate these results through larger clinical trials and mechanistic studies, optimizing treatment protocols.